Navigation Links
Researchers explore connection between popular pain relievers, bladder cancer
Date:11/7/2012

(Lebanon, NH, 11/5/2012) Dartmouth researchers have found that duration of ibuprofen use was associated with a reduced risk of bladder cancer in patients in northern New England, which has a high mortality rate of this disease. In a 2012 collaborative project with the National Cancer Institute, Margaret Karagas, PhD, co-director, Cancer Epidemiology & Chemoprevention program at Norris Cotton Cancer Center, and Professor of Community and Family Medicine at the Geisel School of Medicine at Dartmouth, and Richard Waddell, D.Sc, Research Assistant Professor of Medicine at the Geisel School of Medicine, looked for connections between ibuprofen use and bladder cancer.

Bladder cancer and ibuprofen use

Karagas did an earlier study on the relationship between bladder cancer and nonsteroidal anti-inflammatory drugs (NSAIDs) usage in New Hampshire. The new study included patients in Vermont and Maine. Researchers enrolled 1,171 participants newly diagnosed with bladder cancer and 1,418 participants who did not have bladder cancer. Karagas also added a genetic component looking at thirty-nine genes related to NSAID metabolism and studied a new class of NSAIDs known as selective cyclooxygenase (COX-2) inhibitors, such as celecoxib (Celebrex). Their results were published in the International Journal of Cancer (June 2012).

Those with specific genetic traits appear to have reduced risk

The findings in the recent study suggest that "regular use of nonaspirin nonselective NSAIDs, particularly ibuprofen, may reduce bladder cancer risk, especially among regular users for 10 years or more." However, the study also notes that observed reduction in risk was specific to individuals carrying a specific allele (or variant of a gene) related to NSAID metabolism.

Findings suggest further study needed for newer prescription pain reliever

For Karagas one of the novel findings was a trend of an increased risk of bladder cancer for those using selective COX-2 inhibitors, especially celocoxib (Celebrex). Karagas warns against leaping to any conclusions, noting, "further investigation is needed."

Karagas also stresses that this study "does not make any recommendations. It does not, in any way, suggest that patients begin taking ibuprofen as a prophylactic measure against bladder cancer, nor should patients go off any medicine prescribed by their doctor."


'/>"/>
Contact: Donna Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers discover immune pathway
2. Temple researchers show targeted cancer drug may stunt hearts ability to repair itself
3. Researchers discover how underground rodent wards off cancer
4. Forum to bring together leading-edge ophthalmic researchers and investors
5. George Mason University researchers target breast cancer in 3 trials
6. IU researchers report first effective treatment of tumors arising from common genetic disease NF1
7. OHSU researchers discover potential way to repair brain damage in multiple sclerosis
8. Penn researchers find error reporting improves perceptions of safety and may reduce incidents
9. Common Antidepressants Too Risky During Pregnancy, Researchers Say
10. Mechanism found for destruction of key allergy-inducing complexes, Stanford researchers say
11. Feinstein Institute researchers discover that bean used in Chinese food could protect against sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... All-Star Insurance, a family managed ... clients throughout eastern Texas, is announcing the launch of a new charity drive to ... statistics in the United States reveal that an estimated 252, 710 new cases of ...
(Date:6/22/2017)... ... June 22, 2017 , ... Plastic Surgery Associates is proud to ... for 2017. Each year, research and information firm, Castle Connolly, releases their list of ... 2015, this marks the 3rd time that Dr. Canales has been recognized ...
(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
(Date:6/22/2017)... (PRWEB) , ... June 23, 2017 , ... ... in the fight against hunger on June 21, 2017, at the Emeryville Center ... food insecurity and malnutrition around the world. , Rise Against Hunger (formerly Stop ...
(Date:6/20/2017)... , ... June 20, 2017 , ... After months of negotiations, FaceCradle USA is proud ... on Wednesday, June 21. , “Introducing our product on QVC is something we all ... promote our travel pillow to more than 90 million homes in the United States,” said ...
Breaking Medicine News(10 mins):
(Date:6/8/2017)... 2017  StatLab Medical Products ("StatLab" or ... of diagnostic supplies for the anatomic pathology ... Company LP ("Cressey & Company"), a healthcare-focused ... investment in the Company. Cressey & Company ... selling shareholder, Prairie Capital, L.P., with certain ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:5/30/2017)... , May 30, 2017 Hill-Rom Holdings, Inc. ... Annual Global Healthcare Conference on Tuesday, June 13, 2017, ... John Greisch , Hill-Rom,s president and chief executive officer, is ... The live audio webcast can be accessed at http://ir.hill-rom.com/events.cfm ... conclusion of the live event through September 13, 2017. ...
Breaking Medicine Technology: